Sientra Inc (NASDAQ:SIEN)‘s stock had its “buy” rating reiterated by research analysts at Lake Street Capital in a note issued to investors on Wednesday, August 2nd, MarketBeat Ratings reports. They currently have a $15.00 target price on the medical instruments supplier’s stock, up from their prior target price of $11.00. Lake Street Capital’s target price would indicate a potential upside of 46.77% from the stock’s current price.
A number of other research firms have also issued reports on SIEN. Zacks Investment Research upgraded shares of Sientra from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. ValuEngine upgraded shares of Sientra from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, Stephens initiated coverage on shares of Sientra in a report on Tuesday, July 11th. They issued an “overweight” rating and a $12.00 target price on the stock.
Sientra (SIEN) traded down 1.45% during midday trading on Wednesday, reaching $10.22. 132,576 shares of the company traded hands. The company’s 50-day moving average price is $10.45 and its 200 day moving average price is $8.95. Sientra has a 12 month low of $6.92 and a 12 month high of $11.47. The firm’s market capitalization is $195.53 million.
Sientra (NASDAQ:SIEN) last released its earnings results on Wednesday, August 9th. The medical instruments supplier reported ($0.55) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.04. The company had revenue of $8.20 million for the quarter, compared to analyst estimates of $6.97 million. Sientra had a negative net margin of 152.52% and a negative return on equity of 58.03%. The firm’s revenue for the quarter was up 32.3% on a year-over-year basis. On average, equities analysts anticipate that Sientra will post ($2.31) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.baseball-news-blog.com/2017/08/14/sientra-inc-nasdaqsien-given-buy-rating-at-lake-street-capital-updated.html.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. bought a new position in Sientra during the second quarter worth approximately $101,000. Mission Wealth Management LLC bought a new position in Sientra during the first quarter worth approximately $104,000. Nationwide Fund Advisors increased its position in Sientra by 260.4% in the second quarter. Nationwide Fund Advisors now owns 10,963 shares of the medical instruments supplier’s stock worth $107,000 after buying an additional 7,921 shares in the last quarter. Wells Fargo & Company MN increased its position in Sientra by 0.3% in the first quarter. Wells Fargo & Company MN now owns 12,871 shares of the medical instruments supplier’s stock worth $108,000 after buying an additional 40 shares in the last quarter. Finally, Accredited Investors Inc. bought a new position in Sientra during the second quarter worth approximately $115,000. 77.80% of the stock is owned by institutional investors.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc and related companies with MarketBeat.com's FREE daily email newsletter.